The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
| Autor: | Xi Jin, Youming Li, Kui-fen Ma, Yida Yang, Yue-Fang Ye, Lin Zheng, Yi-peng Chen, Zun Xiang |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Cholagogues and Choleretics Combination therapy Gastroenterology law.invention UDCA Randomized controlled trial law Non-alcoholic Fatty Liver Disease Internal medicine medicine Humans Non-alcoholic steatohepatitis business.industry Fatty liver NASH General Medicine medicine.disease Ursodeoxycholic acid Clinical trial Fatty Liver Treatment Outcome Liver function Steatosis Steatohepatitis business medicine.drug Research Article |
| Zdroj: | BMC Gastroenterology |
| ISSN: | 1471-230X |
| Popis: | Background Non-alcoholic steatohepatitis (NASH) is a condition that occurs during the progression of non-alcoholic fatty liver disease. Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH. Methods Western and Chinese databases were searched by independent investigators using appropriate MESH headings to identify randomized, controlled Western and Chinese clinical trials, published between January 1990 and October 2012, testing the effects of UDCA in patients with NASH. Patient characteristics and trial endpoints were analyzed, with quality assessment according to widely acknowledged criteria. P Results Twelve qualified randomized clinical trials, including six from China and involving 1160 subjects, were selected. Seven of these trials assessed the effects of UDCA Monotherapy, with the other five testing combinations of UDCA with vitamin E, polyene phosphatidylcholine, silymarin, glycyrrhizin and tiopronin. The duration of therapy ranged from 3 to 24 months, with two studies using high doses of UDCA (23–35 mg/kg/d). The average quality point was 2.69, and was significantly lower in articles from China than in those from Western countries (2.2 ± 0.4 vs. 3.8 ± 1.1, respectively, p Conclusions UDCA therapy is effective in NASH, especially when combined with other drugs. However, the low quality of these studies and the heterogeneity of their results precluded further meta-analysis. Additional carefully designed clinical trials are needed, especially in China. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink